Introduction aux nouveaux adjuvants vaccinaux et à leur rôle dans la vaccination antigrippale
Annales Pharmaceutiques Françaises 03/2013; 71(2):104–108. DOI: 10.1016/j.pharma.2013.01.003
New vaccine approaches based on subunit vaccines and on highly purified recombinant proteins use adjuvants to compensate for the loss of immunostimulatory components that are naturally present in whole cell vaccines. The development of adjuvanted influenza vaccines comprising squalene emulsion adjuvants effective against pandemic influenza strains highlights the contribution of novel adjuvants in increasing vaccine coverage by augmenting protection rates and by affording cross-strain protection and antigen dose-sparing. Nevertheless, the development of new adjuvants remains challenging in terms of quality and safety assurance and in terms of clinical and industrial development costs.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.